S

Shandong Boan Biotechnology Co Ltd
HKEX:6955

Watchlist Manager
Shandong Boan Biotechnology Co Ltd
HKEX:6955
Watchlist
Price: 8.86 HKD 0.91% Market Closed
Market Cap: 4.7B HKD
Have any thoughts about
Shandong Boan Biotechnology Co Ltd?
Write Note

Shandong Boan Biotechnology Co Ltd
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shandong Boan Biotechnology Co Ltd
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
S
Shandong Boan Biotechnology Co Ltd
HKEX:6955
Accrued Liabilities
ÂĄ173.5m
CAGR 3-Years
197%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Accrued Liabilities
ÂĄ2.6B
CAGR 3-Years
49%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Accrued Liabilities
ÂĄ1.1B
CAGR 3-Years
8%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Accrued Liabilities
ÂĄ268.5m
CAGR 3-Years
37%
CAGR 5-Years
39%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Accrued Liabilities
ÂĄ325.2m
CAGR 3-Years
-8%
CAGR 5-Years
85%
CAGR 10-Years
60%
Imeik Technology Development Co Ltd
SZSE:300896
Accrued Liabilities
ÂĄ116.1m
CAGR 3-Years
52%
CAGR 5-Years
49%
CAGR 10-Years
N/A
No Stocks Found

Shandong Boan Biotechnology Co Ltd
Glance View

Market Cap
4.5B HKD
Industry
Biotechnology

Shandong Boan Biotechnology Co., Ltd. operates as a biopharmaceutical company that specializes in therapeutic antibody development, manufacturing and commercialization. The company is headquartered in Yantai, Shandong and currently employs 631 full-time employees. The company went IPO on 2022-12-30. The firm is engaged in the development, production and commercialisation of therapeutic antibodies, focusing on the therapeutic areas of oncology, metabolism, autoimmunology and ophthalmology. The firm has three main technology platforms: a fully human antibody transgenic mouse and phage display technology platform, a bispecific T-cell Engager technology platform, and an antibody drug coupling (ADC) technology platform. The firm operates mainly in the domestic Chinese market and overseas markets.

Intrinsic Value
12.74 HKD
Undervaluation 30%
Intrinsic Value
Price
S

See Also

What is Shandong Boan Biotechnology Co Ltd's Accrued Liabilities?
Accrued Liabilities
173.5m CNY

Based on the financial report for Dec 31, 2023, Shandong Boan Biotechnology Co Ltd's Accrued Liabilities amounts to 173.5m CNY.

What is Shandong Boan Biotechnology Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 3Y
197%

Over the last year, the Accrued Liabilities growth was -5%. The average annual Accrued Liabilities growth rates for Shandong Boan Biotechnology Co Ltd have been 197% over the past three years .

Back to Top